NEW YORK (GenomeWeb News) — The Government Accountability Office, the federal watchdog for government spending, said genomic technologies have reduced drug-development productivity while adding to R&D costs in recent years.
 
In a report it issued last month, “New Drug Development: Science, Business and Intellectual Property Issues Cited as Hampering Drug Development Efforts,” the GAO criticizes the slow pace and high costs of drug development and in one section blames genomic technologies.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.